- Home
- XXI vs ADPT Comparison
XXI vs ADPT Comparison
Compare XXI & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XXI | ADPT |
|---|---|---|
| Founded | 2025 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | XXI | ADPT |
|---|---|---|
| Price | $8.30 | $14.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $17.78 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 06-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | N/A | $3.98 |
| Revenue Next Year | N/A | $22.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $5.61 | $8.38 |
| 52 Week High | $11.49 | $20.76 |
Technical Indicators
Market Signals| Indicator | XXI | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 66.53 | 49.54 |
| Support Level | $5.66 | $12.22 |
| Resistance Level | $9.97 | $15.38 |
| Average True Range (ATR) | 0.39 | 0.69 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 91.79 | 54.29 |
Price Performance
Historical ComparisonAbout XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc has no operation history.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.